Hua Yuan - Publications

Clinicopathological characteristics and survival outcomes in early-stage endometrial clear cell carcinoma: a dual-center retrospective study.

Journal: BMC cancer

Published: April 07, 2025

A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective.

Journal: International journal of biological macromolecules

Published: October 30, 2024

Undifferentiated uterine sarcoma : experience of a single center.

Journal: World journal of surgical oncology

Published: August 27, 2024

PARPis after PARPis in patients with recurrent epithelial ovarian cancer: a single institutional experience.

Journal: Journal of ovarian research

Published: August 13, 2024

Prognosis and treatment of uterine sarcoma found incidentally after myomectomy.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: July 22, 2024

Clinical characteristics and treatment outcomes of women with recurrent uterine leiomyosarcoma.

Journal: Orphanet journal of rare diseases

Published: March 17, 2024

Clinicopathological and survival analysis for patients with uterine sarcoma treated following surgery for presumed benign disease.

Journal: BMC cancer

Published: March 08, 2024

Outcomes of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer progressed after prior poly (adenosine diphosphate-ribose) polymerase inhibitors: A retrospective cohort study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: March 04, 2024

Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.

Journal: Journal of ovarian research

Published: January 04, 2024

Sarcoma of the uterine cervix: experience of a single center.

Journal: World journal of surgical oncology

Published: December 18, 2023

Primary fallopian tube cancer followed by primary breast cancer in RAD51C mutation carrier treated with niraparib as first line maintenance therapy: a case report.

Journal: Hereditary cancer in clinical practice

Published: November 24, 2023

PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer.

Journal: Journal of gynecologic oncology

Published: November 22, 2022